The outcome of patients with therapy-related myelodysplasia (t-MDS) or t-AML is very poor. The only curative treatment option implements allogeneic hematopoietic cell transplantation (aHCT); however, long-term follow-up data beyond 5 years are scarce. Here we report on a cohort of 79 consecutive patients with a median age of 58 years (range (r): 20-76) at transplantation and a median follow-up of 7.5 years (r: 0.07-19.0). Only 19 (24.1%) patients were in CR before aHCT. Non-relapse mortality and relapse rates were 23% (95% confidence interval, 15-35%) and 42% (32-55%) at 5 years, and 32% (22-46%) and 44% (34-57%) at 10 years, respectively. Disease-free survival (DFS) and overall survival (OS) rates were 35% (24-46%) and 38% (27-49%) at 5 years, and 24% (14-36%) and 24% (13-36%) at 10 years, respectively. Although cytogenetic aberrations were associated with shorter DFS and higher relapse risk, persistent disease at the time of transplantation, an unrelated donor and patient age were not associated with shorter OS. In conclusion, long-term survival beyond 10 years of t-MDS/t-AML patients after aHCT is possible, even for refractory patients. Therefore, early donor search and rapid transplantation are warranted, also to decrease the risk of disease-related deterioration of patients' performance status.
INTRODUCTION
Cytotoxic agents, especially alkylating and topoisomerase II targeting drugs, as well as ionizing radiotherapy in the successful treatment of most cancer types and to some extent also in nonmalignant diseases, bear a significant long-term risk of developing therapy-related malignancies such as myelodysplasia (t-MDS) and t-AML. 1, 2 Despite intensive efforts to reduce the risk of developing t-MDS/t-AML by using fewer cycles of dose-intense chemotherapy for a given primary disease and thus to decrease cumulative doses, this late occurring side effect remains a challenging clinical problem. 3 Treatment of t-MDS/t-AML, which often occurs with other comorbidities, is complex and the outcome of patients treated with low-or even high-dose chemotherapy alone remains poor. Beyond other factors, this is especially attributed to older age, therapy resistance and cytogenetic abnormalities including monosomies or complex karyotypes. 4, 5 In recent years, it has become evident that the most successful curative treatment concept for t-MDS/t-AML patients resulting in substantial remission rates implements allogeneic hematopoietic cell transplantation (aHCT). Using a myeloablative conditioning regimen in 77% of patients in a cohort of 868 patients with a median age of 40 years, Litzow et al. 6 reported an overall survival (OS) rate of 22% (95% confidence interval (CI), 19-26%) after 5 years, although the non-relapse mortality (NRM) and relapse rate at that time were 48% (95% CI, 44-51%) and 31% (95% CI, 28-34%), respectively. In another study from the European Group for Blood and Marrow Transplantation, Kröger et al. 7 observed a 3 year OS of 35%, a NRM of 37% and a relapse rate of 31% in a comparable cohort of 461 t-MDS/t-AML patients with a median age of 40 years. Congruently, both studies identified higher patients' age, persistent disease at time of transplantation and adverse cytogenetics as the main risk factors for therapy failure.
As long-time follow-up data beyond 5 years after aHCT for t-MDS/t-AML have rarely been reported, we sought to investigate the outcome of those patients who underwent aHCT at our institution between 1995 and 2014.
PATIENTS AND METHODS

Patient characteristics
For the present investigation, conducted in April 2014, we retrospectively analyzed prospectively collected data from our University of Freiburg Medical Center aHCT database and identified 79 unselected, consecutive patients who underwent aHCT for t-MDS/t-AML between 1995 and 2014; their detailed characteristics are displayed in Table 1 .
Twelve patients were diagnosed with t-MDS and 67 patients with t-AML. The median time from the primary disease to t-MDS/t-AML was 6.6 years (range (r): 1.0-41.6). In 43 patients the primary disease was hematologic (non-hodgkin lymphoma: 16, hodgkins lymphoma: 12, AML: 6, ALL: 5 and severe aplastic anemia: 4), whereas 29 patients had suffered from previous solid cancers (breast: 20, colon: 1, head/neck: 2, prostate: 1, testicular: 3, thymic: 1 and ovarian: 1). Seven patients were initially diagnosed with a non-malignant disease (chronic bowel disease: 2, encephalomyelitis disseminata: 1, rheumatologic disease (systemic lupus, rheumatoid arthritis and polymyalgia rheumatic): 3 and sclerotic kidney disease: 1). All patients had been treated with systemic chemotherapy and/or local radiation and, in the case of non-malignant disease, with long-term immunosuppression including methotrexate (MTX) and cyclosporine A. As the aim of the analysis was to include unbiasedly all patients with the diagnosis of t-MDS/t-AML who were transplanted at our center, patients without a malignant primary disease but who were pretreated with MTX, were not excluded. At the time of transplantation, the primary malignancy was in remission in all patients.
According to the Southwest Oncology Group criteria, 8 46.6% of patients (24.7% out of which with normal karyotype) had an intermediate-risk karyotype, 53.4% had an adverse-risk karyotype and for six patients the karyotype was missing. The median duration between diagnosis of t-MDS/ t-AML and transplantation was 143 days (r: 8-776) and the median age at the time of transplantation of the 38 male and 41 female patients was 58 years (r: 20-76); of note, 28 patients (35.4%) were 465 years. None of the patients had undergone aHCT before. Before transplantation, 65.8% of patients had received an induction or low-dose (cytarabine, hydroxyurea, 5-azacytidine and decitabine) chemotherapy, whereas 34.2% remained untreated. At the time of transplantation, 24% of patients were in CR, 29.1% had primary induction failure, 12.7% had progressive disease and 34.2% were untreated.
The performance status according to the Karnofsky score was ⩾ 90% in 49 patients (62%) and ⩽ 80% in 30 patients (38%). Implementing the hematopoietic cell transplantation comorbidity index (HCT-CI), 22.8% of patients had a score of ⩽ 3, 30.4% had a score of 4-5 and 46.8% had a score of 6-8.
Conditioning regimens and GvHD prophylaxis
Twenty-one patients (26.6%) had received a busulphan/cyclophosphamide-based myeloablative conditioning regimen; in detail: 18 patients received either oral (16 mg/kg bw (body weight)) or IV (12.8 mg/kg bw) busulphan with cyclophosphamide (120 mg/kg bw); two patients received oral busulphan (12 mg/kg bw), cyclophosphamide (90 mg/kg bw) and fludarabine (60 mg/m 2 (meter-squared body-surface)); and one patient received TBI (12 Gy), etoposidphophate (40 mg/kg bw) and cyclophosphamide (50 mg/kg bw). Abbreviations: aHCT = allogeneic hematopoietic cell transplantation; ATG = anti-thymocyte globulin; CsA = cyclosporine A; HCT-CI = hematopoietic cell transplantation comorbidity index; MMF = mycophenolate mofetil; MTX = methotrexate; PD = progressive disease; PIF = primary induction failure; r = range; t-AML = therapy-related AML; t-MDS = therapy-related myelodysplasia. Mismatched unrelated donor: 1-2 mismatches; for graft size, data for 1 BM and 69 PBSC were available.
of the MTX and MMF receiving patients additionally received anti human T-lymphocyte immunglobulin (ATG) 10-60 mg/kg bw (Grafalon, Neovii Biotech, Munich, Germany) as previously described. 10 In two patients, immunosuppression without cyclosporine A consisted of MMF plus everolimus, and mini-MTX, ATG 60 mg plus tacrolimus, respectively. Supportive care, prophylactic antibiotics and, in case of CMV infection pre-emptive therapy, with ganciclovir or foscarnet, were given to patients according to previously described standards. 9 Acute GvHD was assessed according to criteria of the International Bone Marrow Transplantation Registry and chronic GvHD (cGvHD) was classified as limited or extensive according to Shulman et al.
11,12
The applied transplantation and immunosuppression protocols were approved by the Freiburg University Medical Center institutional review board and ethics committee. All patients had given written informed consent for data collection and treatment in compliance with the Declaration of Helsinki.
Donor and graft characteristics
Until 2009, HLA-I Ags A and B were either typed by serology or intermediate-resolution DNA techniques (two digits) and thereafter as for the HLA-II Ags DRB1 and DQB1, with high-resolution DNA techniques (four digits). Donors were HLA-identical siblings (n = 21), HLA-identical matched unrelated donors (HLA-A, -B, -DRB1 and DQB1; n = 37) and mismatched (1-2 mismatches) unrelated donors (n = 21, Table 1 ). The graft source was G-CSF-mobilized unmanipulated PBSC in 71 patients and bone marrow stem cells in eight patients. The median donor age was 40 years (r: 19-73). In total, 20 of 38 (52.6%) male patients received a graft from female donors, 20 of 41 (48.8%) female patients received grafts from male donors and 39 patients had same-sex donors. Sixty-four patients (81%) were at risk for CMV reactivation (CMVpositive recipient or donor). The median number of transfused CD34+ cells was 6.8 × 10
6 /kg bw (r: 1.6-17.0; data available for one bone marrow donor and 69 PBSC donors).
Statistical analysis
This is a retrospective analysis of all patients who underwent aHCT for t-MDS/t-AML between 1995 and 2014 at the University of Freiburg Medical Center. It was the aim to describe the long-term prognosis of these patients with respect to OS time, disease-free survival (DFS) time, time to NRM and time to relapse. All times were calculated from aHCT, until death for OS, until relapse or death for DFS, until death without previous relapse for NRM and until relapse for relapse. For patients not experiencing the respective event, time to last follow-up was used as censored observation.
Another aim was to evaluate the prognostic effect of the following baseline characteristics at time of transplantation on OS, DFS, NRM and relapse: year of aHCT, patient's age, remission status at aHCT (CR vs no CR), Karnofsky index (⩾90 vs ⩽ 80), HCT-CI (4-8 vs 0-3), cytogenetics (intermediate/adverse vs normal karyotype) and donor source (unrelated vs related). The prognostic effects of the factors with respect to the timeto-event variables were analyzed with Cox regression models for the event-specific hazard functions using two-sided Wald tests. To estimate the effect sizes, the hazard ratios (HRs) between groups defined by the prognostic factors were calculated with 95% CIs. Univariate analyses of the factors, evaluating their effects separately, and multiple regression analyses, evaluating their simultaneous effect, were performed.
OS rates and DFS rates were estimated by the Kaplan-Meier method. NRM and relapse rates were estimated by cumulative incidences; both considering the opposite event as competing. Since mortality within the first year after transplantation is usually high, we also analyzed conditional survival, that is, the OS probability after having survived 1 and 2 years after transplantation.
All analyses are exploratory without former sample size planning. No adjustment for multiple testing was performed. All P-values have to be interpreted in a descriptive sense. Statistical analyses were performed using the Statistical Analysis System, version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Engraftment
With the exception of one patient who had to be regrafted after primary graft failure, all patients were engrafted with a WBC count of ⩾ 1.0 × 10 9 /L on median day +15 (r: 10-28). In 22 patients, G-CSF was given starting on day +7; in two patients G-CSF was started on day +2. Stable platelet counts (⩾20.0 × 10 9 /L) were reached on median day +16 (r: 7-55; n = 71).
Response CR on day +30 based on standard morphologic criteria was reached in 71 patients (89.9%), two patients (2.5%) had progressive disease, four patients (5.1%) died before response evaluation between day +26 and +48, and in two patients response assessment was not performed.
GvHD
Grade II-IV acute GvHD requiring treatment occurred in 20 of 79 patients (25.3%) and grade III-IV acute GvHD in eight patients (10.1%). In this cohort, no patient died because of acute GvHD. Of 66 evaluable patients, 16 (24.2%) developed limited cGvHD and 17 (25.6%) extensive cGvHD over the whole observation period. Two patients died because of cGvHD.
Follow-up, OS, NRM, relapse and causes of death The median follow-up of the entire cohort was 7.5 years (r: 0.07-19.0) and median survival was 2.4 years (Figure 1) . At the time of analysis in April 2014, 26 patients (32.9%) were alive with a median follow-up of 5.8 years, of whom 23 were in CR and three had suffered relapse. Follow-up was complete for all patients until the data cutoff date 01 April 2014. Thirty patients had died after relapse, and 23 patients had died without previous relapse. The median age at transplantation of patients who survived 45 years (n = 23) was 50 years (r: 20-71) and the cause of death in those patients is listed in Table 2 . The rate of cGvHD in patients who survived 45 years was 69.6%. Ten-year survivors (n = 8) had a median age at transplantation of 44 years (r: 20-71) and only 25% had an adverse-risk karyotype.
Cumulative DFS and OS rates were 35% (95% CI, 24-46%) and 38% (27-49%) at 5 years, and 24% (14-36%) and 24% (13-36%) at 10 years, respectively ( Table 3 ). The cumulative NRM and relapse rate were 23% (15-35%) and 42% (32-55%) at 5 years, and 32% (22-46%) and 44% (34-57%) at 10 years, respectively. It is of note that the survival probabilities increased when patients had survived the first year. The conditional 10 year survival probability increased from 24% (unconditional) to 36% and 46% (conditional on having survived 1 and 2 years after transplantation).
Thirty-three patients suffered a relapse and multiple donor lymphocyte infusions (DLI) were given to 26 patients. Eleven patients underwent secondary aHCT with 2/11 achieving a sustained remission 412 month. The causes of death (n = 53) were relapse (42.3%), infections (21.2%), organ failure (13.5%), primary malignancy (5.8%, all breast cancer), tertiary malignancy (5.8%, hypopharyngeal carcinoma: 1, tongue carcinoma: 1 and Years post transplantation Figure 1 . Overall survival rate of the entire cohort. Median follow-up of 7.5 years is marked. Median overall survival was 2.4 years.
EBV-associated post-transplant lymphoproliferative disorder: 1), cGvHD (3.8%), central nervous system complications (3.8%, Alzheimer's disease: 1 and cerebral infarction: 1) and two unknown ( Table 2) .
Univariate and multivariate analysis of patient, disease and donor factors Regarding OS, DFS and NRM, no effects with P o 0.05 could be detected in univariate analyses. There appeared to be a slight association of a Karnofsky score ⩾ 90% and decreased NRM (HR, 0.46; 95% CI, 0.20-1.05; P = 0.07) and longer DFS (HR, 0.60; 95% CI, 0.36-1.02; P = 0.06), whereas for the HCT-CI, no association could be observed. Intermediate or adverse cytogenetics also seem to be associated with shorter DFS (HR, 2.04; 95% CI, 0.96-4.34; P = 0.06; Table 4 , Figure 2e ). Regarding the risk of relapse, there was an effect of the CR status at time of aHCT (HR, 2.97; 95% CI, 1.04-8.06; P = 0.04) and of the cytogenetic risk group (HR, 3.52; 95% CI, 1.07-11.61; P = 0.04; Figures 2c and f) . It is of note that a non-related donor (matched unrelated donor or MMUR (mismatched unrelated donor)) resulted in a slightly decreased relapse rate (HR, 0.54; 95% CI, 0.26-1.12; P = 0.10) and increased DFS rate (HR, 0.65; 95% CI, 0.36-1.17; P = 0.15), suggesting that non-related donors are at least at no disadvantage for aHCT in t-MDS/t-AML patients (Figures 2h and i) .
Results of multivariate analyses were in general similar to results of univariate analyses ( Table 4) . The association between a Karnofsky score ⩾ 90% and decreased NRM was slightly stronger (HR, 0.30; 95% CI, 0.11-0.82; P = 0.02), whereas the association between intermediate/adverse cytogenetics and an increased relapse rate (HR, 2.76; 95% CI, 0.77-9.82; P = 0.12) and a decreased DFS rate (HR, 2.02; 95% CI, 0.89-4.58; P = 0.09) were less pronounced as compared with the univariate analyses. Regarding DFS (HR, 0.68; 95% CI, 0.36-1.27; P = 0.22) and relapse (HR, 0.55; 95% CI, 0.25-1.23; P = 0.14), a non-related donor did not appear to be a disadvantage also in multivariate analyses. In our cohort, the year of transplantation did not seem to have an effect on outcome. However, it is of note that the median age of patients at aHCT increased overtime (Table 1) .
Finally, for the factors CR at time of aHCT (HR, 1.03; 95% CI, 0.50-2.11; P = 0.94), transplantation from an unrelated donor (matched unrelated donor or mismatched unrelated donor; HR, 0.72; 95% CI, 0.38-1.35; P = 0.31) and patient's age (HR, 1.03; 95% Abbreviations: DFS = disease-free survival; NRM = non-relapse mortality; OS = overall survival; REL = relapse. All values are represented as % (95% confidence interval, CI). CI, 0.80-1.34; P = 0.81), no association with OS was observed (Figures 2a and g ).
DISCUSSION
During the past two decades, several groups have demonstrated that aHCT as a curative approach for patients with t-MDS/t-AML is a feasible and, regarding 5 year OS data, a promising therapeutic concept. 6, 7, [13] [14] [15] [16] Here we present a retrospective long-term followup analysis of 79 unselected consecutive t-MDS/t-AML patients who underwent aHCT after predominantly RIC (73.4%) between 1995 and 2014. With a median follow-up of 7.5 years, this is one of the longest reported follow-up studies for this specific patient clientele, revealing a 10 year OS and DFS rate of 24% (13-36%) and 24% (14-36%), respectively, whereas the NRM rate was 32% (22-46%). Regarding the 5 year time point, our data show a slightly higher OS and DFS rate, a lower NRM rate but a higher relapse rate, than previously reported by Litzow et al. 6 Beyond others, this can be explained by the less toxic conditioning that was used in the majority of patients in our study. Although one of the limitations of the present study is the small patient number as compared with our colleagues, the inclusion of all patients irrespective of primary diagnosis until 2014, the predominance of RIC, the comparably high median age and the very long followup are novel and may reflect the current clinical practice more precisely. Furthermore, the relatively low NRM rate (23% at 5 years and 32% at 10 years) is remarkable considering the median age of 58 years and aHCT-CI of 43 in 77.2% of patients.
An European Group for Blood and Marrow Transplantation study on t-MDS/t-AML patients after aHCT with a median age of 40, reported 3 year OS and DFS rates of 35% and 33%, respectively, corresponding well to our data, and NRM and relapse rates of 37% and 31%, respectively. 7 As in the other studies, relapse was the major cause of death in our study, followed by infections. Although survival maybe prolonged, post-relapse therapies with DLIs and secondary aHCT remained generally disappointing with only two sustained remissions after second transplantation. Newer relapse concepts implement hypomethylating agents such as 5-azacytidine before DLI infusion, resulting in promising long-term remission rates in a subset of patients. 17 However, preventing the occurrence of relapse should be the primary goal of future concepts. In this regard, several groups are investigating the role of 5-azacytidine as part of a maintenance treatment after allogeneic hematopoietic cell transplantation in high-risk AML patients as demethylating agents have been shown to increase the GvL effect while reducing GvHD. 18, 19 The role of lenalidomide as potential immunomodulator after allogeneic hematopoietic cell transplantation remains Long-term follow-up of t-MDS/t-AML patients after aHCT J Finke et al controversial as it not only increased the GvL effect, but also resulted in increased GvHD. 20 Finally, a promising approach in reducing relapse rates could be vaccination concepts with peptides such as WT-1, which is highly expressed in the majority of AML. 21 It is of note that three patients died after aHCT because of a tertiary malignancy: in two patients, a solid cancer of the tongue and hypopharynx occurred, respectively, most likely not due to the pre-therapy but rather due to lifestyle, whereas one patient developed an EBV-associated post-transplant lymphoproliferative disorder.
Previous studies have convincingly demonstrated that abnormal cytogenetics is one of the major risk factors predicting higher relapse rates and shorter OS. 6, 7 Despite the small sample size, this was also the case in univariate and multivariate analyses in our cohort. Although it remains controversial whether allogeneic stem cell transplantation can alleviate the negative prognostic impact of adverse cytogenetics, it was recently demonstrated that leukemia stem cells, which are thought to account for relapse after therapy, highly express leukemiaassociated Ags and could be targeted by T cells. 22 Furthermore, leukemia-associated Ags-peptide specific T cells were detected in nearly all AML patients after allogeneic stem cell transplantation, supporting the concept of potential immunologic control of highrisk AML after aHCT. 23 Although higher patient age was not associated with shorter OS in our cohort, interestingly CR at the time of aHCT was not a positive factor for OS, although it was associated with a lower relapse rate in the univariate analysis. Although this could be attributed to intensive post-relapse therapy, another reason maybe the fact that a substantial number of deaths (23 out of 53) did not occur after relapse, and no effect of CR status on NRM was present. Nonetheless, our data warrant further analyses to investigate whether patients who are not in CR and have a suitable donor should undergo aHCT. Moreover, as patients with t-MDS/t-AML mostly harbor monosomies and complex karyotypes and as these karyotype abnormalities are often associated with poor response rates upon intensive induction chemotherapy, recent and ongoing studies evaluate the value of, for example, hypomethylating drugs as a bridging strategy until aHCT can be conducted. [24] [25] [26] [27] Despite the identification of prognostic factors in t-MDS/t-AML patients undergoing aHCT, the question remains, which cancer patients are especially at risk for developing t-MDS/ t-AML. Recently, it was demonstrated that genetic profiling of CD34+ cells, including genes related to hematopoietic regulation and metabolism, can identify patients who are at risk for this secondary complication after previous chemotherapy already before overt t-MDS/t-AML. 28 This is of importance because evaluation of eligibility for transplantation or donor search could be initiated early in patients at risk.
In accordance with other studies, we also did not see a negative influence of the donor type (matched unrelated donor/mismatched unrelated donor vs MRD) on OS, DFS and relapse. 6, 29 Thus, early non-related donor search should be conducted, if there is no matching related donor.
Unexpectedly, our patients' performance status analysis revealed that it was not the HCT-CI that predicted increased NRM, but the Karnofsky score before conditioning. Although these results may be unreliable due to a small sample size and in part retrospective collection of HCT-CI data, we suspect that in a cohort No   19  14  10  8  7  5  4  2  2  2  2  60  35  25  21  19  18  16  10  7  7  5   19  13  10  8  7  5  4  2  2  2  2  60  24  20  19  17  16  14  9  6  6  5   19  13  10  8  7  5  4  2  2  2  2  60  24  20  19  17  16 with predominantly RIC, the HCT-CI variables (comorbidities in patients' medical history) may have a weaker impact on chemotherapy tolerance and toxicity than the actual performance status at time of transplant according to Karnofsky. 30 In summary, we show that aHCT after RIC can result in longterm survival 410 years in up to 24% (11-36%) of t-MDS/t-AML patients. Refractory patients who are not in CR at the time of transplantation should not be precluded from aHCT, especially if the Karnofsky score is ⩾ 90%. As an unrelated (well-) matched donor does not seem to be a disadvantage regarding outcome, early non-related donor search and rapid transplantation in t-MDS/t-AML patients are indicated, also to reduce the risk of t-MDS/t-AML-related deterioration of the patients' performance status.
